Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany.

ABSTRACT:

Context

Efficacy and safety of once-weekly semaglutide in type 2 diabetes were established in the phase 3 SUSTAIN trials, which included patients across the continuum of type 2 diabetes care. It is useful to complement these findings with real-world evidence.

Objective

SURE Germany evaluated once-weekly semaglutide in a real-world type 2 diabetes patient population.

Design/setting

The prospective observational study was conducted at 93 clinical practices in adults with+≥ 1 documented glycated haemoglobin value ≤12 weeks before initiation of semaglutide.

Intervention

Once-weekly semaglutide was prescribed at the physicians' discretion.

Main outcomes

The primary endpoint was change in glycated haemoglobin from baseline to end-of-study (~30 weeks). Secondar

SUBMITTER: Menzen M 

PROVIDER: S-EPMC10101737 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature